A phase I, open-label, multi-center, dose escalation study of oral NVP-CGM097, a p53/HDM2-protein-protein interaction inhibitor, in adult patients with selected advanced solid tumors

被引：8

作者：

Bauer, S. ^{[1
]}

Demetri, G. ^{[2
]}

Jeay, S. ^{[3
]}

Dummer, R. ^{[4
]}

Guerreiro, N. ^{[3
]}

Tan, D. S. ^{[5
]}

Kumar, A. ^{[6
]}

Meille, C. ^{[3
]}

Van Bree, L. ^{[3
]}

Halilovic, E. ^{[7
]}

Wuerthner, J. U. ^{[3
]}

Cassier, P. ^{[8
]}

机构：

[1] Univ Klinikum Essen, Internal Med, Essen, Germany

[2] Dana Farber Canc Inst, Ludwig Ctr, Boston, MA 02115 USA

[3] Novartis Pharma AG, Basel, Switzerland

[4] Univ Zurich Hosp, Zurich, Switzerland

[5] Natl Canc Ctr, Singapore, Singapore

[6] Novartis Healthcare Pvt Ltd, Hyderabad, Andhra Pradesh, India

[7] Novartis Inst BioMed Res, Cambridge, MA USA

[8] Ctr Leon Berard, Lyon, France

来源：

关键词：

D O I：

10.1093/annonc/mdw368.9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

366PD

引用

页数：1